Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy” by Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $27.1429.

ZVRA has been the subject of a number of recent research reports. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday. Cantor Fitzgerald lifted their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Finally, Guggenheim dropped their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Friday, August 7th.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director Corey Michael Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director owned 1,800 shares in the company, valued at approximately $20,250. The trade was a 87.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ZVRA. Adage Capital Partners GP L.L.C. lifted its position in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Zevra Therapeutics by 4.4% during the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after purchasing an additional 130,676 shares in the last quarter. Nantahala Capital Management LLC raised its stake in Zevra Therapeutics by 34.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares during the period. Rubric Capital Management LP lifted its holdings in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares in the last quarter. Finally, State Street Corp lifted its holdings in Zevra Therapeutics by 3.9% in the 4th quarter. State Street Corp now owns 1,482,956 shares of the company’s stock worth $13,287,000 after purchasing an additional 55,665 shares in the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $11.87 on Wednesday. The business’s fifty day moving average is $12.23 and its 200 day moving average is $10.77. Zevra Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $15.03. The company has a market capitalization of $704.84 million, a PE ratio of 12.90 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.The business had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. On average, sell-side analysts forecast that Zevra Therapeutics will post 0.72 EPS for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.